Published in HIV Med on April 01, 2008
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother (2012) 0.95
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr (2012) 0.95
Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med (2011) 0.91
Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med (2014) 0.86
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr (2010) 0.86
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med (2016) 0.83
Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet (2014) 0.80
Evaluation of nevirapine dosing recommendations in HIV-infected children. Br J Clin Pharmacol (2013) 0.77
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother (2016) 0.75
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med (1999) 4.12
Reduced lopinavir exposure during pregnancy. AIDS (2006) 3.98
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr (2003) 3.21
Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol (2005) 2.51
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS (1999) 2.23
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 2.18
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos (1999) 1.73
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr (2004) 1.60
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis (2004) 1.30
Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials (2001) 1.30
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol (2002) 1.23
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med (2006) 1.19
Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol (2005) 1.18
Transplacental passage of protease inhibitors at delivery. AIDS (2002) 1.12
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother (2005) 1.09
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS (2006) 0.96
Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta (2005) 0.93
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther (2002) 0.81
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Genome sequence and comparative analysis of the solvent-producing bacterium Clostridium acetobutylicum. J Bacteriol (2001) 6.46
Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother (1991) 6.41
Prevalence of specific language impairment in kindergarten children. J Speech Lang Hear Res (1997) 6.37
Long-term developmental outcome of infants with iron deficiency. N Engl J Med (1991) 5.51
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 5.31
An integrated computational pipeline and database to support whole-genome sequence annotation. Genome Biol (2002) 5.24
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med (1999) 5.05
Increased bone formation in osteocalcin-deficient mice. Nature (1996) 4.91
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Open-reading-frame sequence tags (OSTs) support the existence of at least 17,300 genes in C. elegans. Nat Genet (2001) 4.03
Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics (2000) 3.79
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes Dev (1990) 3.50
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med (1995) 3.28
Detection of human cytomegalovirus in clinical specimens by DNA-DNA hybridization. J Infect Dis (1984) 3.10
The risk of childhood cancer after neonatal exposure to vitamin K. N Engl J Med (1993) 3.09
Private health care in developing countries. BMJ (2001) 2.89
Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet (1998) 2.84
Human immunodeficiency virus infection of human-PBL-SCID mice. Science (1991) 2.77
A protein-protein interaction map of the Caenorhabditis elegans 26S proteasome. EMBO Rep (2001) 2.74
Iron deficiency anemia and iron therapy effects on infant developmental test performance. Pediatrics (1987) 2.74
Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut (2003) 2.74
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Preventing child abuse and neglect with a program of nurse home visitation: the limiting effects of domestic violence. JAMA (2000) 2.50
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS (2000) 2.49
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet (2003) 2.38
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis (1997) 2.31
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS (1999) 2.23
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis (1997) 2.14
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis (1990) 2.08
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes. J Biol Chem (1994) 2.06
Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci. J Infect Dis (1989) 2.04
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol (1999) 2.04
Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation (1993) 2.02
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Rate of Glycolate Formation During Photosynthesis at High pH. Plant Physiol (1966) 1.94
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis (1993) 1.93
Prevalence of psychiatric disorders among persons convicted of driving while impaired. Arch Gen Psychiatry (2001) 1.93
Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol (1988) 1.92
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology (2007) 1.90
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.88
Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology (2000) 1.88
Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint-switch models, genetic counseling, and prenatal diagnosis. Am J Hum Genet (1998) 1.87
Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res (2001) 1.85
Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception (1990) 1.84
Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction. J Clin Microbiol (1989) 1.81
Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices (2009) 1.81
Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob Agents Chemother (1990) 1.80
Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis (1995) 1.79
Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr (2001) 1.78
New charts for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a population-based cohort study. Ultrasound Obstet Gynecol (2008) 1.73
Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol Cell Biol (2000) 1.73
Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol (1995) 1.72
CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr (1999) 1.67
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Human endogenous retroviral element K10 (HERV-K10) encodes a full-length gag homologous 73-kDa protein and a functional protease. AIDS Res Hum Retroviruses (1993) 1.63
A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood. Neurology (1989) 1.62
The representation of pleasant touch in the brain and its relationship with taste and olfactory areas. Neuroreport (1999) 1.61
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Antioxidant properties of a North American ginseng extract. Mol Cell Biochem (2000) 1.57
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2001) 1.54
The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report. Cancer Clin Trials (1980) 1.54
Home use of rectal diazepam to prevent status epilepticus in children with convulsive disorders. J Child Neurol (1989) 1.53
Antidepressant analgesia in rheumatoid arthritis. J Rheumatol (1988) 1.53
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS (1999) 1.50
Defects in mouse mammary gland development caused by conditional haploinsufficiency of Patched-1. Development (1999) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Postzoster cutaneous pseudolymphoma. Arch Dermatol (1994) 1.50
Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem (1988) 1.49
Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection. J Clin Microbiol (1987) 1.49
Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen. J Exp Med (1976) 1.48